Philogen attends the SITC Annual Meeting in November 2022.
Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma”.
Roberto De Luca, PhD, Head of Antibody Therapeutics at Philogen, to present an abstract entitled “A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer”.
Sheila Dakhel, PhD, Senior Scientist at Philogen, to present an abstract entitled “Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation”.
Abdullah Eisayed, PhD student at Philogen, to present an abstract entitled “A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in cancer immunotherapy”.
Please visit the conference Website for more details.